Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
Hg18
Hg18 Feb. 4 at 2:52 PM
$FBIOP any sense of when EMA will approve Unloxcyt?
0 · Reply
FinSUN
FinSUN Feb. 3 at 10:46 PM
$FBIOP this is a safe port at least
0 · Reply
Zellchair
Zellchair Feb. 3 at 9:11 PM
$FBIO $FBIOP 4. US Senate and House have pass the Mikaela Naylon “Give Kids a Chance Act” to extend the rare pediatric disease priority review voucher program to September 2029. 5. A medical paper has been published in a Medical Journal regarding PD-1/PD-L1 highlighting the benefits of UNLOXCYT. 6. Blue Cross and BCN have added UNLOXCYT to their utilization management medical drug list. 7. It has continued to write several articles on the ASH new guidelines for AL Amyloidosis. And then I'm sure I missed a lot...
1 · Reply
Zellchair
Zellchair Feb. 3 at 9:09 PM
$FBIO $FBIOP One of the stupidest posts I've read here. I've been following Fortress for 2 years. Almost every weekday there is news that can be directly or indirectly traced to Fortress' subsidiaries, associated companies and pipelines. In addition to what I wrote here yesterday, this has only happened in the last 24 hours: 1. Triplex's closest commercial competitor PREVYMIS reported sales of $275M in Q4 2025 (+28%), $978M for the full year 2025 (+25%) for Merck. 2. Dotinurad's closest commercial competitor KRYSTEXXA reported sales of $435M in Q4 2025 (+26%), $1.34B for the full year 2025 (+13%) for Amgen. 3. A newspaper article has been written about Triplex's competitor mRNA-1647, a focused attention on only one organic possible growth area for Moderna, CMV. Moderna is valued at about 17,500% more (market cap in common shares) where the hope (at least in the article) is directed at CMV. Fortress (Helocyte) has better data, a long lead in time and significantly more indications for CMV.
0 · Reply
Alex1m2
Alex1m2 Feb. 3 at 3:49 PM
$FBIOP $FBIO Zell has opened his subst. again.
1 · Reply
Sawnchey
Sawnchey Feb. 2 at 9:37 PM
$FBIO $FBIOP For anyone more knowledgeable than me, just for some fun speculation, is there any legal reason why they couldn't buy out Avenue [maybe also one day Mustang] and take them private? Avenue in particular is essentially sat there burning cash and waiting for either Axsome to develop BAER-101 or some investor to hand them 100m to fund its P3. Since its market cap is curently a fraction of shareholder equity, surely it would be more efficient to just bring the whole thing back into the fold, cease ongoing operations and retain full control of the IP and assets? It seems the better option than holding onto a 10% stake in a zombie company. Hell if I had a million dollars (and FBIO didn’t have a perpetual voting control) I would try it myself. So I am just wondering if there is some sort of anti-fraud regulation that stops them from doing that sort of thing?
1 · Reply
makrodimutross
makrodimutross Feb. 2 at 8:58 PM
$FBIOP $FBIO it will also benefit the company if they sell the PRV After March, because Cyprium PPS would only roll into FBIOP shares instead of being redeemed at 2x liquidation preference. This conversation sounds unusual to me. In essence, LR seems to be saying "the shareholders can wait to be paid." How about he does the same thing with Cyprium PPS then. Save the company plenty of cash to help them develop the AAV-ATP7 platform. Don't sell the PRV until after March... since it's "in the best interest of the company".
1 · Reply
Zellchair
Zellchair Feb. 2 at 4:43 PM
$FBIO $FBIOP $DERM Andrew Summers of Summers Value Partners keeping his focus and belief in EMROSI: https://www.readideabrunch.com/p/idea-brunch-with-andrew-summers-of
0 · Reply
Zellchair
Zellchair Feb. 2 at 4:42 PM
$FBIO $FBIOP Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites From today: https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-phase-3-ruby-study-with-first-patients-dosed-at-european-sites-302674720.html
0 · Reply
Zellchair
Zellchair Feb. 2 at 4:40 PM
$FBIO $FBIOP $CKPT Sun Pharma reported for the period Oct-Dec 2025 this weekend. Although they never give sales guidance, much of the UNLOXCYT content was worth listening to. For minute markers, listen between the minutes in earnings call: 10-11 23-25 29-30 35-36 41-42 https://sunpharma.com/wp-content/uploads/2026/01/FY26-Q3-Earnings-Call-Recording-10039711.mp3
1 · Reply
Latest News on FBIOP
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 10:41 PM EST - 2 months ago

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

FBIO


Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 11 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO


Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 3 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO


Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 7 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO


Hg18
Hg18 Feb. 4 at 2:52 PM
$FBIOP any sense of when EMA will approve Unloxcyt?
0 · Reply
FinSUN
FinSUN Feb. 3 at 10:46 PM
$FBIOP this is a safe port at least
0 · Reply
Zellchair
Zellchair Feb. 3 at 9:11 PM
$FBIO $FBIOP 4. US Senate and House have pass the Mikaela Naylon “Give Kids a Chance Act” to extend the rare pediatric disease priority review voucher program to September 2029. 5. A medical paper has been published in a Medical Journal regarding PD-1/PD-L1 highlighting the benefits of UNLOXCYT. 6. Blue Cross and BCN have added UNLOXCYT to their utilization management medical drug list. 7. It has continued to write several articles on the ASH new guidelines for AL Amyloidosis. And then I'm sure I missed a lot...
1 · Reply
Zellchair
Zellchair Feb. 3 at 9:09 PM
$FBIO $FBIOP One of the stupidest posts I've read here. I've been following Fortress for 2 years. Almost every weekday there is news that can be directly or indirectly traced to Fortress' subsidiaries, associated companies and pipelines. In addition to what I wrote here yesterday, this has only happened in the last 24 hours: 1. Triplex's closest commercial competitor PREVYMIS reported sales of $275M in Q4 2025 (+28%), $978M for the full year 2025 (+25%) for Merck. 2. Dotinurad's closest commercial competitor KRYSTEXXA reported sales of $435M in Q4 2025 (+26%), $1.34B for the full year 2025 (+13%) for Amgen. 3. A newspaper article has been written about Triplex's competitor mRNA-1647, a focused attention on only one organic possible growth area for Moderna, CMV. Moderna is valued at about 17,500% more (market cap in common shares) where the hope (at least in the article) is directed at CMV. Fortress (Helocyte) has better data, a long lead in time and significantly more indications for CMV.
0 · Reply
Alex1m2
Alex1m2 Feb. 3 at 3:49 PM
$FBIOP $FBIO Zell has opened his subst. again.
1 · Reply
Sawnchey
Sawnchey Feb. 2 at 9:37 PM
$FBIO $FBIOP For anyone more knowledgeable than me, just for some fun speculation, is there any legal reason why they couldn't buy out Avenue [maybe also one day Mustang] and take them private? Avenue in particular is essentially sat there burning cash and waiting for either Axsome to develop BAER-101 or some investor to hand them 100m to fund its P3. Since its market cap is curently a fraction of shareholder equity, surely it would be more efficient to just bring the whole thing back into the fold, cease ongoing operations and retain full control of the IP and assets? It seems the better option than holding onto a 10% stake in a zombie company. Hell if I had a million dollars (and FBIO didn’t have a perpetual voting control) I would try it myself. So I am just wondering if there is some sort of anti-fraud regulation that stops them from doing that sort of thing?
1 · Reply
makrodimutross
makrodimutross Feb. 2 at 8:58 PM
$FBIOP $FBIO it will also benefit the company if they sell the PRV After March, because Cyprium PPS would only roll into FBIOP shares instead of being redeemed at 2x liquidation preference. This conversation sounds unusual to me. In essence, LR seems to be saying "the shareholders can wait to be paid." How about he does the same thing with Cyprium PPS then. Save the company plenty of cash to help them develop the AAV-ATP7 platform. Don't sell the PRV until after March... since it's "in the best interest of the company".
1 · Reply
Zellchair
Zellchair Feb. 2 at 4:43 PM
$FBIO $FBIOP $DERM Andrew Summers of Summers Value Partners keeping his focus and belief in EMROSI: https://www.readideabrunch.com/p/idea-brunch-with-andrew-summers-of
0 · Reply
Zellchair
Zellchair Feb. 2 at 4:42 PM
$FBIO $FBIOP Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites From today: https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-phase-3-ruby-study-with-first-patients-dosed-at-european-sites-302674720.html
0 · Reply
Zellchair
Zellchair Feb. 2 at 4:40 PM
$FBIO $FBIOP $CKPT Sun Pharma reported for the period Oct-Dec 2025 this weekend. Although they never give sales guidance, much of the UNLOXCYT content was worth listening to. For minute markers, listen between the minutes in earnings call: 10-11 23-25 29-30 35-36 41-42 https://sunpharma.com/wp-content/uploads/2026/01/FY26-Q3-Earnings-Call-Recording-10039711.mp3
1 · Reply
Sawnchey
Sawnchey Feb. 2 at 9:01 AM
$FBIO $FBIOP I had this article appear in my inbox this morning: https://www.medscape.com/viewarticle/cmv-most-important-virus-no-one-talks-about-2026a10002ni?ecd=a2a Important to remember how much activity is going on at Fortress, Helocyte has already completed 4 studies of their Triplex vaccine for CMV, the FBIO corporate presentation also inclues Clinicaltrials codes for 8 additional trials, which if you click through most are recruiting still but the Adult HIV Phase 2 study completed enrollment further in the past than the primary endpoint window and so data should be ready at any moment. Fortress owns 83% of Helocyte, so this is another significant potential market opportunity which is reflected by roughly zero in the stock price.
0 · Reply
Zellchair
Zellchair Jan. 26 at 12:15 PM
$FBIO $FBIOP - Dotinurad is expected in studies to have a major impact on controlling Gout over a longer period of time. - Dotinurad is already used off label in Chronic Kidney Disease (CKD) in Japan. If it can be proven in a larger randomized study this is "huge and could affect a much larger population of people who are whose kidneys are basically failing. And if we can actually stop that decline in the kidney function, then that would be a real gamechanger as well." Try to remember here my previous posts about not stopping at Gout and specifically the evidence and theories that already exist for Dotinurad in CKD.
1 · Reply
makrodimutross
makrodimutross Jan. 25 at 4:35 PM
$FBIOP Lindsay Rosenwald held 127,500 shares of FBIOP as of July 2024. If the PRV is sold by the end of March to provide Cyprium PPS their 2x liquidation preference, and the Fortress BOD votes to become current on their dividends in arrears to the preferred shareholders at some point in April... 21 months of dividends in arrears is $4.10 per share. Rosenwald will receive a net payment of $522,949. Likewise, if the company decides to fully redeem the shares, it would cost the company the $25 liquidation preference, plus the $4.10 in arrears, just shy of $100M in cash (less likely), Rosenwald would receive $3.7M. The company will likely lay out a plan similar to Care Cloud's in November (catch up / doubled payments until the arrears have been satisfied). I doubt they will redeem. Fortress is looking more like the retirement plan for Rosenwald and Weiss with each passing month.
1 · Reply
Zellchair
Zellchair Jan. 24 at 3:05 PM
$FBIO $FBIOP Perhaps it is appropriate to update the "fair value" in Q4? “Urica valued its equity holding in Crystalys using an option pricing model backsolve method (level 3 in the fair value hierarchy) to reassess the fair value of its investment in Crystalys after Crystalys announced a Series A financing and recognize additional shares received to maintain its 15% ownership percentage under the APA, resulting in an estimated fair value of $15.1 million which was recorded as other income in the condensed consolidated statement of operations during the three and nine months ended September 30, 2025” – Fortress Biotech Q3 2025, P. 21-22 https://www.fortressbiotech.com/investors/sec-filings/quarterly-reports
1 · Reply
Zellchair
Zellchair Jan. 24 at 3:02 PM
$FBIO $FBIOP Crystalys Therapeutics "With a current valuation of $800M, the company has demonstrated strong market traction and investor confidence." https://salestools.io/en/report/crystalys-therapeutics-205m-series-a https://pitchbook.com/profiles/company/897186-34#overview Before (importantly) SOBI bid for Arthrosi for up to $1.5B in December (expected to close in Q1), Crystalys was valued at $800M by PitchBook and Salestools after the latest Series A round. Now the floor should be set well above Arthrosis $1.5B (in my opinion). https://www.sobi.com/en/press-releases/sobi-acquire-arthrosi-therapeutics-strengthening-pipeline-potential-treatment-gout-2413046 CFO recruitment and CEO attendance whisper about IPO and/or buyout before IPO. https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-leadership-team-with-appointment-of-justin-thacker-as-chief-financial-officer-to-support-advancement-of-phase-3-trials-of-dotinurad-302665997.html https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-1-capital-allocation-and-dealmaking-U3B4EUN3GZGNXM6QI3ZGXVMNZY/ Dotinurad is already validated with 17 studies in Japan alone (excluding those in the US, China, Thailand & the Philippines).
1 · Reply
Zellchair
Zellchair Jan. 24 at 1:57 PM
$FBIO $FBIOP “According to Sentynl, the product is expected to launch by early March.” https://www.clinicaladvisor.com/news/first-treatment-for-menkes-disease-fda-approves-copper-histidinate/
0 · Reply
Zellchair
Zellchair Jan. 24 at 1:55 PM
$FBIO $FBIOP $DERM "Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed" https://seekingalpha.com/article/4862086-journey-medical-emrosi-winning-stock-has-not-noticed
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 12:17 PM
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 5:28 AM
0 · Reply
Sawnchey
Sawnchey Jan. 23 at 12:29 PM
$FBIO $FBIOP I'm quite surprised they haven't PR'd the launch of Unloxcyt yet. This is material news for the company and could really help drive interest between Zycubo approval and PRV sale. I think one of the reasons that these stocks trend towards undervaluation is the combination of the complex ownership structure of assets, and a relatively quiet Fortress management team. There hasn't been a broad public event in the last 6 months despite numerous developments, and I think it would be very helpful if there were to be more communication from the team to help the market understand what the value proposition is here.
2 · Reply
Chaka1647
Chaka1647 Jan. 22 at 8:33 PM
$DERM up 16% in the last month .... another tailwind for $FBIOP lets hope the increase is real and not just random walk
1 · Reply
FinSUN
FinSUN Jan. 21 at 4:55 PM
0 · Reply